COMMUNIQUÉS West-GlobeNewswire

Helix BioPharma Corp. Closes Private Placement
10/09/2018
RICHMOND HILL, Ontario, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and [...]
BioSig Technologies, Inc. Announces 1-for-2.5 Reverse Stock Split for Pending Uplist to Nasdaq
10/09/2018
Split-Adjusted Common Stock trading under BSGMD on September 11, 2018 Santa Monica, CA, Sept. 10, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM, OTCQB: BSGMD) (“BioSig” or the “Company”), a medical [...]
Clearside Biomedical to Participate in 2018 Janney Healthcare Conference
10/09/2018
ALPHARETTA, Ga., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye [...]
PLx Pharma Inc. to Present at Janney Healthcare Conference on September 18
10/09/2018
HOUSTON, Sept. 10, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 [...]
ERYTECH Reports First Half of 2018 Financial Results and Provides Business Update
10/09/2018
Conference call and webcast scheduled for Tuesday, September 11 th at 2:30 pm CET/8:30 am EDT Strategic shift to development of eryaspase for solid tumors confirmed Phase 3 trial for eryaspase in second line pancreatic [...]
ERYTECH publie ses résultats financiers et fait le point sur ses activités du premier semestre 2018
10/09/2018
Conférence téléphonique et webcast : mardi 11 septembre à 14h30 Confirmation du virage stratégique entrepris vers le développement d’eryaspase dans les tumeurs solides Lancement de l’étude de Phase 3 avec eryaspase pour [...]
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology
10/09/2018
The interference proceeding remains terminated without any determination on inventorship of CRISPR/Cas9 genome editing application to eukaryotic cells University of California/University of Vienna/Dr. Charpentier have [...]
Endocyte Announces $175.0 Million Proposed Public Offering of Common Stock
10/09/2018
WEST LAFAYETTE, Ind., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today that [...]
Avid Bioservices Reports Financial Results for First Quarter Fiscal 2019 and Recent Developments
10/09/2018
-- F iscal 2019 Projected Revenue of $51 to $55 Million Reaffirmed -- -- Multiple Projects Advanced During the Quarter -- -- Initiated Operations of New Process Development Laboratories -- TUSTIN, Calif., Sept. 10, 2018 [...]
AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2018
10/09/2018
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV [...]
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/09/2018
MENLO PARK, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies [...]
Trevena to Present Oliceridine, a Next Generation IV Opioid for the Management of Moderate to Severe Acute Pain, at FDA Advisory Committee Meeting on October 11, 2018
10/09/2018
CHESTERBROOK, Pa., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), today announced that the U.S. Food and Drug Administration (FDA) has scheduled a meeting of the Anesthetic and Analgesic Drug Products [...]
Integra LifeSciences Selected for Healogics iSupply℠ Program
10/09/2018
PLAINSBORO, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced it has been selected as a primary provider for [...]
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
10/09/2018
MENLO PARK, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced that it intends to offer and sell shares of its common stock in an underwritten public [...]
Vilacto Bio Introduces New LACTOACTIVE iTHER® Compound
10/09/2018
COPENHAGEN, Denmark, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Vilacto Bio Inc. (OTC QB:VIBI) has launched its LACTOACTIVE iTHER® product. LACTOACTIVE iTHER® is a new LACTOACTIVE variant that combines potent immune-system [...]
RespireRx Pharmaceuticals Inc. Secures Clinical and Commercial Supply of Dronabinol for Obstructive Sleep Apnea with the Signing of a Development and Supply Agreement with Noramco, Inc.
10/09/2018
Glen Rock, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- September 10, 2018 /Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on September 4, 2018, it [...]
CORRECTING and REPLACING – HempAmericana CEO Issues Letter on Shift to Commercial-Stage Operations
10/09/2018
NEW YORK, Sept. 10, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- HempAmericana, Inc. (OTC:HMPQ) (“HempAmericana” or the “Company”) CEO issues the following letter to Shareholders: Dear Valued Shareholder, Last week, we [...]
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Affirms Favorable U.S. Patent and Trademark Office Decision in CRISPR Interference
10/09/2018
CAMBRIDGE, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed the U.S [...]
HEXO acquires interest in 2M sq. ft. facility in Belleville, Ontario to create R&D and manufacturing centre of excellence
10/09/2018
GATINEAU, Quebec, Sept. 10, 2018 (GLOBE NEWSWIRE) -- HEXO Corp. (“HEXO” or the “Company”) (TSX:HEXO) has announced the acquisition of an interest in a 2,004,000 sq. ft. facility in Belleville, Ontario. This is the first [...]

Pages